Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Ebola disease: bridging scientific discoveries and clinical application.

Rojek A. et al, (2024), The Lancet. Infectious diseases

Vaccine Platform Comparison: Protective Efficacy against Lethal Marburg Virus Challenge in the Hamster Model.

O'Donnell KL. et al, (2024), International journal of molecular sciences, 25

Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses

Dijokaite-Guraliuc A. et al, (2023), Cell Reports, 42, 112271 - 112271

Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster

Ulaszewska M. et al, (2023), Human Vaccines & Immunotherapeutics

Serum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro.

Nyagwange J. et al, (2022), International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6.

Dijokaite-Guraliuc A. et al, (2022), Cell discovery, 8

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females

Marchevsky NG. et al, (2022), eBioMedicine, 81, 104128 - 104128

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

Tuekprakhon A. et al, (2022), Cell, 185, 2422 - 2433.e13

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees

Nutalai R. et al, (2022), Cell, 185, 2116 - 2131.e18

Viral vector vaccines.

McCann N. et al, (2022), Current opinion in immunology, 77

Load More